Medication Returns, Waste and Disposal: Introduction 101
SKS Medication Safety Series, Chapter 14 of 15 · Standard SİY13, SİY15
Prof. Dr. Mehmet Nurullah Kurutkan, Düzce Üniversitesi İşletme Fakültesi Sağlık Yönetimi Bölümü
Chapter at a glance
Medicines that are returned, left over, expired or spoiled must be recorded and disposed of safely. This is the least studied part of the medication-use process. This chapter covers returns to pharmacy, waste reduction and disposal. It corresponds to SKS SİY13 (returns) and SİY15 (waste and expired medicines) (Sağlık Bakanlığı, 2020).
Evidence base: 38 records of a 4948-record Web of Science corpus on hospital medication safety (Section 7). Reading time: about 25 minutes. Prior knowledge required: none.
Learning objectives
After working through this chapter, the reader should be able to:
- state the SKS SİY13 and SİY15 requirements;
- explain why medication waste matters for safety, cost and the environment;
- describe evidence on returns review and waste reduction;
- identify links between waste and controlled drug diversion.
Key concepts
- Returned medicine: a dispensed dose sent back to pharmacy
- Pharmaceutical waste: unused, expired or partially used medicines for disposal
- Disposal record: documentation of name, quantity, reason, method, unit, date and person
- Intravenous push waste: residual drug discarded after a partial dose
- Leftover medicines: unused medicines kept in homes
Contents: How this chapter was produced · 1. Introduction · 2. History and development · 3. Definitions and conceptual schema · 4. Distinguishing it from neighbouring concepts · 5. Types and classifications · 6. Theoretical frameworks and models · 7. Themes and bibliometric profile · 8. The situation in Türkiye · 9. Debates and contradictions in the literature · 10. Measurement problems · 11. Research gaps and agenda · 12. Implications for practice today · Summary · Discussion questions · Further reading · Glossary · References · Source verification and AI use statement · Data and supplementary material
How this chapter was produced
Box 1. Method
Database: Web of Science Core Collection (SCI-EXPANDED, SSCI, ESCI); English; articles and reviews (including early access). Search date: 16 November 2026; all years (1981 to 2027).
Search: (#1 medication safety and error terms AND #2 hospital settings AND #3 fifteen SKS content blocks) NOT #4 animal and preclinical terms; the full string is on the series hub.
Screening: five export files (4955 records) were merged; 7 duplicates were removed by WoS accession number, DOI and normalised title plus year, leaving 4948 records. Records were assigned to this sub-topic when its term set (pharmaceutical, drug or medication waste, disposal, unused medicines, returned medicines, leftover) appeared in the title or keywords or, for this thin sub-topic, the abstract; a record can belong to several sub-topics. Included here: 38 records (8 with the term in the title; 4 reviews).
Limitations: single database; English only; assignment by term matching, checked by reading titles of the most cited and most recent records; claims are checked against abstracts, not full texts.
4955 records
8 title matches; 4 reviews
other chapters or general records
1. Introduction
SKS requires a defined process for receiving medicines returned to the pharmacy and records of returns (Sağlık Bakanlığı, 2020), and a defined process and rules for disposing of medication waste and expired medicines, with disposal records including drug name, quantity, reason, method, unit, date and responsible person (Sağlık Bakanlığı, 2020).
Returns and waste are often treated as logistics, but the corpus shows three safety links: returned doses can reveal missed administrations (Gilliand et al., 1992), waste of controlled drugs creates diversion risk (Hertig et al., 2025), and leftover medicines at home create poisoning risks (Renny et al., 2022).
2. History and development
A 1992 programme reviewed returned doses with a log sheet (Gilliand et al., 1992). Lean process improvement reduced waste and inventory in an inpatient pharmacy in 2009 (Hintzen et al., 2009). Since 2020 studies have used infusion pump data to reduce waste (Forshay et al., 2020), measured the workforce burden of intravenous push controlled substance waste (Hertig et al., 2021; Hertig et al., 2025), linked intraoperative opioid waste with outcomes (Redaelli et al., 2024) and addressed antimicrobial waste and sustainability (Plattner et al., 2024).
- 1992 Programme for reviewing returned medications (Gilliand et al., 1992).
- 2009 Lean techniques reduce waste in an inpatient pharmacy (Hintzen et al., 2009).
- 2020 Infusion pump data used to reduce drug and fluid waste (Forshay et al., 2020).
- 2021 Workflow time study of IV push waste (Hertig et al., 2021).
- 2024 Intraoperative opioid waste and outcomes (Redaelli et al., 2024); antimicrobial waste review (Plattner et al., 2024).
- 2025 Multi-site study of IV push controlled substance waste costs (Hertig et al., 2025).
3. Definitions and conceptual schema
| Source | Year | Discipline | Definition (paraphrased) | Emphasised dimension |
|---|---|---|---|---|
| Sağlık Bakanlığı, 2020 | 2020 | Accreditation standard | Defined processes for returned medicines and for disposal of waste and expired drugs, with full disposal records. | Process and records |
| Gilliand et al., 1992 | 1992 | Hospital pharmacy | Returned doses as information to be logged and explained. | Information source |
| Forshay et al., 2020 | 2020 | Hospital pharmacy | Waste as excess drug and fluid preparable through standardised concentrations. | Avoidable surplus |
| Hertig et al., 2025 | 2025 | Pharmacy operations | Controlled substance waste as an operational burden linked to documentation and diversion risk. | Control burden |
| Plattner et al., 2024 | 2024 | Paediatric infectious diseases | Antimicrobial waste as a financial and environmental cost reducible by stewardship. | Sustainability |
medicines that leave the use process unused are recorded, explained and disposed of safely, and avoidable surplus is reduced
SKS treats returns and waste as processes to document (Sağlık Bakanlığı, 2020); recent research treats them as signals of inefficiency and risk (Forshay et al., 2020; Hertig et al., 2025).
4. Distinguishing it from neighbouring concepts
Returns and waste overlap most with preparation and dispensing, where surplus arises, and with controlled drugs, whose waste must be witnessed and documented (Figure 4).
| Neighbouring concept | How it differs |
|---|---|
| Storage (SİY04) | Separation of expired stock precedes disposal (Sağlık Bakanlığı, 2020). |
| Controlled drugs (SİY11) | Destruction of narcotics must be recorded (Sağlık Bakanlığı, 2020). |
| Stewardship (SİY01.02) | Can reduce antimicrobial waste (Plattner et al., 2024). |
5. Types and classifications
The records distinguish returned doses (Gilliand et al., 1992), preparation and infusion surplus (Forshay et al., 2020), partial-dose controlled substance waste (Hertig et al., 2021) and household leftovers (Renny et al., 2022).
6. Theoretical frameworks and models
Lean process improvement is the main framework (Hintzen et al., 2009); sustainability thinking frames antimicrobial waste (Plattner et al., 2024).
7. Themes and bibliometric profile
With 38 records this is the smallest sub-topic (Figure 5). Smaller syringe sizes for intraoperative opioids may reduce waste, costs and adverse outcomes (Redaelli et al., 2024); standardised concentrations and bag sizes reduced drug and fluid waste across hospitals (Forshay et al., 2020).
Records per year 2026 (incomplete)
Most frequent journals
Most frequent countries
Most frequent author keywords: medication management (5), medication safety (5), quality improvement (3), waste (3), sustainability (3), medication errors (3), patient safety (3), pharmacy administration (2), qualitative research (2), communication (2).
8. The situation in Türkiye
No record has a Turkish address. Practices under SKS SİY13 and SİY15 have not been evaluated in the indexed literature captured here.
9. Debates and contradictions in the literature
Cost or safety? Most studies justify waste reduction economically (Forshay et al., 2020); few measure safety effects, an exception being opioid waste and postoperative outcomes (Redaelli et al., 2024).
Hospital or home? Hospital disposal is regulated, but leftover medicines are common in homes and caregivers rarely receive disposal guidance (Renny et al., 2022).
10. Measurement problems
Waste is measured in cost, volume or staff time (Hertig et al., 2021; Hertig et al., 2025). No standard indicator of returns or disposal quality appears in the corpus.
11. Research gaps and agenda
- What do returned doses reveal about missed administrations in Turkish hospitals? (Gilliand et al., 1992)
- How complete are SKS disposal records? (no study found)
- Can product size standardisation reduce controlled drug waste and diversion? (Hertig et al., 2025)
- What is the environmental footprint of hospital pharmaceutical waste? (Plattner et al., 2024)
- How should discharge education address leftover medicines? (Renny et al., 2022)
12. Implications for practice today
Log and review returns (Gilliand et al., 1992); match product sizes to common doses (Hertig et al., 2021); standardise infusion concentrations (Forshay et al., 2020); integrate waste into stewardship (Plattner et al., 2024); and give patients disposal advice at discharge (Renny et al., 2022).
Summary
- Returns and waste are the least studied medication processes.
- SKS SİY13 and SİY15 require processes and complete records.
- Waste is linked to cost, diversion and environmental harm.
- Standard concentrations and product sizes reduce waste.
- No Turkish study exists in the corpus.
Discussion questions
- What safety information can returned doses provide?
- Why is controlled substance waste a diversion risk?
- Propose indicators for SİY15.
- How could your hospital reduce antimicrobial waste?
- What should patients be told about leftover medicines?
Further reading
- (Gilliand et al., 1992): an early returns review programme.
- (Forshay et al., 2020): data-driven waste reduction.
- (Hertig et al., 2025): costs of controlled substance waste.
- (Redaelli et al., 2024): links waste and outcomes.
- (Plattner et al., 2024): sustainability perspective.
Glossary
| Turkish | English | Short definition |
|---|---|---|
| İade edilen ilaç | Returned medicine | Dispensed dose sent back |
| İlaç atığı | Pharmaceutical waste | Medicines for disposal |
| İmha kaydı | Disposal record | Documentation of destruction |
| Artık ilaç | Leftover medicine | Unused medicine at home |
References
Forshay, C. M., Hansen, K. N., & Eckel, S. F. (2020). Using intravenous pump infusion data to optimize continuous infusion concentrations and reduce drug and fluid waste. American Journal of Health-System Pharmacy, 77(18), 1497-1503. https://doi.org/10.1093/ajhp/zxaa199
Gilliand, B. F., Stanislav, G. H., Constantin, J. J., & Schwinghammer, T. L. (1992). Program for reviewing returned medications. American Journal of Hospital Pharmacy, 49(4), 860-863. https://doi.org/10.1093/ajhp/49.4.860
Hertig, J., Jarrell, K., Arora, P., Nwabueze, J., Moureaud, C., Degnan, D. D., & Trujillo, T. (2021). A Continuous Observation Workflow Time Study to Assess Intravenous Push Waste. Hospital Pharmacy, 56(5), 584-591. https://doi.org/10.1177/0018578720931754
Hertig, J., Louden, L., Shay, B., Soto, A., Doan, T., & Gross, Z. (2025). Assessing Pharmacy Costs of Intravenous Push Controlled Substance Waste in Hospital-Based Areas: A Multi-Site Study. Pharmacy, 13(5), Article 121. https://doi.org/10.3390/pharmacy13050121
Hintzen, B. L., Knoer, S. J., Van Dyke, C. J., & Milavitz, B. S. (2009). Effect of lean process improvement techniques on a university hospital inpatient pharmacy. American Journal of Health-System Pharmacy, 66(22), 2042-2047. https://doi.org/10.2146/ajhp080540
Plattner, A. S., Davidge, K. N., Schweiger, J. A., & Macbrayne, C. E. (2024). Prescribing a Green Future: A Review of Antimicrobial Waste in Pediatric Hospitals and Practices to Promote Healthcare Sustainability. Journal of the Pediatric Infectious Diseases Society, 13(11), 561-567. https://doi.org/10.1093/jpids/piae074
Redaelli, S., Suleiman, A., Von Wedel, D., Ashrafian, S., Munoz-Acuna, R., Chen, G. Q., Khany, M., Stewart, C., Ratajczak, N., Hertig, J., Nabel, S., Schaefer, M. S., & Ramachandran, S. K. (2024). Intraoperative Opioid Waste and Association of Intraoperative Opioid Dose with Postoperative Adverse Outcomes: A Hospital Registry Study. Pain and Therapy, 13(2), 211-225. https://doi.org/10.1007/s40122-023-00574-2
Renny, M. H., Thaker, R. H., & Dayan, P. S. (2022). Caregiver Practices and Knowledge Regarding Leftover Prescription Medications in Homes With Children. Pediatric Emergency Care, 38(9), E1557-E1563. https://doi.org/10.1097/PEC.0000000000002680
Sağlık Bakanlığı. (2020). Sağlıkta kalite standartları: Hastane (Sürüm 6.1). Sağlık Hizmetleri Genel Müdürlüğü, Sağlıkta Kalite, Akreditasyon ve Çalışan Hakları Dairesi Başkanlığı. https://dosyamerkez.saglik.gov.tr/Eklenti/41258/0/skshastane-seti-s-61–09082021pdf.pdf
Source verification and AI use statement
Source verification. All 9 references were generated programmatically from the Web of Science records of the corpus, so authors, year, title, journal and DOI match the records exactly; every in-text citation was cross-checked by code against the reference list. Claims were checked against the record abstracts; full texts were not read. The SKS Hospital Set (Version 6.1) is the only source outside the corpus; it was accessed and read for this chapter.
AI use statement. Claude (Anthropic) was used to merge and de-duplicate the Web of Science exports, assign records to sub-topics, compute the bibliometric indicators and figures, and draft the text under the author’s instructions. The author is responsible for the final content.
Data and supplementary material
Supplementary file S1 (Excel) lists the 38 records of this chapter (authors, year, title, journal, DOI, title match flag), together with the full screening log of the 4948-record corpus and the citation verification report. The list is not reproduced here; it is available from the author on request.
← Chapter 13: Patients’ Own Medicines and Medication ReconciliationChapter 15: Medication Error Reporting, Traceability and Indicators →